Clinical Demonstrations of Controlled-Release Tablets Constructed by the Combined Usage of Shellac and Hydroxypropyl Methylcellulose

نویسندگان

چکیده

A new tablet system was examined for an intestinal delivery using hydroxypropyl methylcellulose (HPMC) and shellac. HPMC incorporated into the inside of tablet, shellac coated on surface, which evaluated its controlled-release property through several dissolution tests, firstly in vitro then via two kinds clinical studies with healthy volunteers. The were originally designed by employing X-ray photography movements tablets gastrointestinal tract electronical device to easily analyze absorption profile glucose, a model compound. It found that strongly suppressed simulated gastric fluid (pH 1.2) subsequently started disintegrate 6.8). first human study revealed could pass stomach without disintegrating. controlled release further confirmed analyses AUC, Cmax, Tmax blood glucose concentration other AUC Cmax significantly reduced our system, thus concluding combined addition coating unequivocally leads tract.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

In Vitro Studies of Controlled Release Alfuzosin Matrix Tablets Prepared with Ethylcellulose and Hydroxypropyl Methylcellulose

      Extended release formulation of alfuzosin, an a-antagonist used for prostatic hypertrophy, is available in market. It is convenient for older patients to take only one tablet a day. Marketed alfuzosin formulation is three layered geomatrix tablet that requires special facilities, high cost, more time and complex operation than normal direct compression formulation. Therefore, a less compl...

متن کامل

Formulation and Evaluation of Hydroxypropyl Methylcellulose-based Controlled Release Matrix Tablets for Theophylline

The objectives of the study were to formulate hydroxypropyl methyl cellulose-based controlled release matrix tablets for theophylline with varying drug:polymer ratios (1:1 and 1:2) and differing tablet hardness (5, 6 and 7 kg/cm(2)), and to evaluate the tablet's physico-chemical properties such as hardness, uniformity of weight, friability, drug content and in vitro drug release. Initially, gra...

متن کامل

Design and Evaluation of Hydroxypropyl Methylcellulose Matrix Tablets for Oral Controlled Release: A Historical Perspective

Hydrophilic matrix tablets (matrices) for oral use are designed to hydrate on swallowing, and form a ‘gel’ layer of hydrated polymer at the tablet surface to control the rate of drug release during passage of the matrix through the gastrointestinal tract. During gastrointestinal transit, the matrices are reduced in size through surface erosion and dissolution. This reduces the probability of ex...

متن کامل

Design and in vitro evaluation of zidovudine oral controlled release tablets prepared using hydroxypropyl methylcellulose.

Oral controlled release matrix tablets of zidovudine were prepared using different proportions and different viscosity grades of hydroxypropyl methylcellulose. The effect of various formulation factors like polymer proportion, polymer viscosity and compression force on the in vitro release of drug were studied. In vitro release studies were carried out using United States Pharmacopeia (USP) typ...

متن کامل

in vitro studies of controlled release alfuzosin matrix tablets prepared with ethylcellulose and hydroxypropyl methylcellulose

extended release formulation of alfuzosin, an a-antagonist used for prostatic hypertrophy, is available in market. it is convenient for older patients to take only one tablet a day. marketed alfuzosin formulation is three layered geomatrix tablet that requires special facilities, high cost, more time and complex operation than normal direct compression formulation. therefore, a less complicated...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Future Pharmacology

سال: 2021

ISSN: ['2673-9879']

DOI: https://doi.org/10.3390/futurepharmacol1010005